In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Increased cardiac mass and abnormal vascular function in women after preeclampsia

Session Poster session 3

Speaker Thomas Gero Von Lueder

Congress : EuroEcho-Imaging 2017

  • Topic : cardiovascular disease in special populations
  • Sub-topic : Pregnancy and Cardiovascular Disease
  • Session type : Poster Session
  • FP Number : P844

Authors : TG Von Lueder (Oslo,NO), K Angel (Oslo,NO), K Moe (Oslo,NO), P Alnaes-Katjavivi (Oslo,NO), G Storvold (Oslo,NO), M Sugulle (Oslo,NO), C Redman (Oxford,GB), R Dechend (Berlin,DE), A Staff (Oslo,NO), D Atar (Oslo,NO)

15 views

Authors:
TG Von Lueder1 , K Angel1 , K Moe2 , P Alnaes-Katjavivi3 , G Storvold4 , M Sugulle3 , C Redman5 , R Dechend6 , A Staff2 , D Atar2 , 1Oslo University Hospital, Department of Cardiology - Oslo - Norway , 2University of Oslo, Faculty of Medicine - Oslo - Norway , 3Oslo University Hospital, Division of Obstetrics and Gynaecology - Oslo - Norway , 4Oslo University Hospital, Institute for Experimental Medical Research - Oslo - Norway , 5University of Oxford - Oxford - United Kingdom , 6Charite University Hospital, Experimental and Clinical Research Center, Charité Medical Faculty and Max-Delbrueck Center for Mol - Berlin - Germany ,

Citation:
European Heart Journal Supplements ( 2017 ) 18 ( Supplement 3 ), iii209

Background: Following pregnancies complicated with preeclampsia, women are at increased risk of cardiovascular (CV) disease. The underlying mechanisms and temporal changes of CV phenotypes in such at-risk population are little studied.

Purpose: This study aims to describe the CV phenotype of women following pregnancy complicated with preeclampsia (PRE).

Methods: Demographics, blood pressure, echocardiography and vascular function in women 1 year after abnormal pregnancy complicated by PRE and after normal pregnancy were compared. Setting: large tertiary university hospital.

Results: see table: In PRE, several CV structural and functional parameters indicate increased cardiac mass and vascular stiffening. Higher, although not abnormal blood pressure may contribute.

Conclusions: This work demonstrates several structural and functional CV abnormalities with putative clinical relevance in women at 1 year after pregnancy complicated by PRE. The data support high clinical vigilance to detect evolving CV disease in these women.

Parameter

Controls (n = 38)

PRE (n = 44)

Age (y)

35±1

35±1

MAP, mean arterial blood pressure (mmHg)

78±1

87±1*

HR, heart rate (beats/min)

67±1

71±2

Rate-pressure product (mmHg/min)

7159±167

8450±292*

Echocardiography

IVSD, interventricular septum diameter (mm)

6.2±0.1

6.9±0.1**

LVEDD, LV end-diastolic diameter (mm)

48.5±0.6

47.7±0.6

RWT, relative wall thickness

0.26±0.01

0.29±0.01**

LVM, LV mass (g)

98±3

108±3*

LVEF, LV ejection fraction (%)

63±0.5

63±0.5

LVSV, LV stroke volume (mL)

68±2

64±1*

E/A ratio

1.83±0.06

1.68±0.06a

LV global myocardial performance (Tei) index

0.38±0.02

0.43±0.02*

LVSW, LV stroke work (mL)

92±2

100±3*

Vascular function

PWV, pulse wave velocity (m/s)

6.1±0.1

6.5±0.2*

AIX, augmentation index (%)

10.5±1.9

15.4±1.3*

AoBPsys,systolic aortic blood pressure (mmHg)

94.8±1.3

104.5±1.8***

Values are means ± SEM. LV, left ventricle. *P<0.05, **P<0.01, ***P <0.0001; PRE versus controls (unpaired t-test).

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are